Kura Oncology, Inc.·4

Aug 14, 4:05 PM ET

WILSON TROY EDWARD 4

4 · Kura Oncology, Inc. · Filed Aug 14, 2025

Insider Transaction Report

Form 4
Period: 2025-08-12
WILSON TROY EDWARD
DirectorPresident and CEO
Transactions
  • Purchase

    Common Stock

    2025-08-12$5.85/sh+36,506$213,57837,474 total
  • Purchase

    Common Stock

    2025-08-13$6.64/sh+13,494$89,62350,968 total
Holdings
  • Common Stock

    (indirect: By Trust)
    279,194
  • Common Stock

    (indirect: By Trust)
    300,000
Footnotes (3)
  • [F1]This transaction was executed in multiple trades at prices ranging from $5.56 to $5.995. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F2]Includes 409 shares acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F3]This transaction was executed in multiple trades at prices ranging from $6.485 to $6.735. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4